B7-2/CD86 Antibody (1029808) [Alexa Fluor® 700]

• Reactivity: Pm-Cm
• Applications: WB, IHC, KO
• Clone: 1029808
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

B7-2/CD86 Antibody (1029808) [Alexa Fluor® 700] Summary

• Immunogen: Human embryonic kidney cell HEK293-derived cynomolgus monkey B7-2/CD86 protein
  Leu20-His239
  Accession # XP_005548057
• Specificity: Detects cynomolgus monkey B7-2/CD86 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Knockout Validated
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for B7-2/CD86 Antibody (1029808) [Alexa Fluor® 700]

• Activation B7-2 antigen
• B70
• B7-2 antigen
• B72
• B7-2
• B-lymphocyte activation antigen B7-2
• BU63
• CD28 antigen ligand 2
• CD28LG2B7-2 antigen)
• CD86 antigen
• CD86 molecule
• CD86
• CTLA-4 counter-receptor B7.2
• FUN-1
• LAB72
• MGC34413
• T-lymphocyte activation antigen CD86

Background

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Within the ECD, cynomolgus B7-2 shares 96%, 57%, and 56% amino acid sequence identity with human, mouse and rat B7-2, respectively. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (2-5), as well as on vascular endothelial cells (6). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3, 5, 7-9). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3, 5, 7, 8). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (10). B7-2 is expressed earlier than B7-1 following APC activation (4), and both proteins bind with higher affinity to CTLA-4 than to CD28 (8). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (11). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (12). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (13).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • XP_005548057()